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A new combinatorial approach for the biosynthesis and screening of small drug-like toxin 
inhibitors inside living cells is presented. This approach has been initially used as proof of 
principle for finding inhibitors against the LF factor from Bacillus anthracis. 
Key to our ‘living combinatorial’ approach is the use of a living cell as a micro-chemical factory 
for both synthesis and 
screening of potential 
inhibitors for a given 
molecular recognition 
event (see Scheme 1). 
This powerful 
technique posses the 
advantage that both 
processes synthesis 
and screening happen 
inside the cell thus 





Introduction and motivation 
Deliberate exposure of the civilian population of the United States to B. anthracis spores 
by means of the United States Postal Service revealed a gap in the nation’s overall preparedness 
against bioterrorism. Unfortunately, anthrax is just one of many potential weapons of biochemical 
terrorism, there are so many other toxins like ricin or botulin that could also be used against the 
civilian population. This alarming situation uncovers an urgent need for tests to rapidly diagnose, 
effective antidotes or vaccines to prevent, and drugs to cure disease (like new antiviral/antibiotics 
against new pathogenic bacterial or viral strains). Thus, the development of new methodologies 
for fast and efficient synthesis, and screening of small drug-like molecules with high affinity 
against toxins should be one of the top priorities in the fight against bioterrorism. These 
molecules could be used as specific antidotes but also, when attached to the appropriate platform, 
as reliable biosensors.  
In order to be useful, these new methodologies should be fast -allowing high throughput 
analysis- and efficient, i.e. provide specific binders in a short period of time. The available 
methods for solving this daunting problem are either based on rational or combinatorial 
approaches. The rational approach uses the molecular structure of the target to be knocked out, 
and then using docking software is able to find potential binders within a virtual library of small 
organic molecules. Despite the big advances in computing technology, however, this is still a 
Scheme 1 
slow process yielding around one ligand per year. Furthermore, most of the docking software 
available is based on static docking programs, which reduces considerably the efficiency of this 
technique.1 Combinatorial approaches, on the other hand, use a random approach to generate as 
many compounds as possible with the hope that some of the members in these huge mixtures of 
compounds (also called libraries) will have activity against the molecular target (this is a common 
approach in nature, active antibodies are created and selected in that way). Combinatorial 
libraries can be generated using chemical2 or biological3 tools. Chemical generation of libraries is 
usually generated in solid-phase and consequently the libraries are limited to contain 106 different 
compounds as maximun.2 Biological libraries can reach up to 109 members per library (as in 
phage display technology) however are limited to the generation of peptide or proteins libraries 
only. In both cases, however, the main limitation is the screening process, which is carried in 
vitro and is very time consuming. 
As solution we have developed  totally new and revolutionary approach, a living 
combinatorial approach. This approach uses living cells for the generation of libraries of small 
drug-like biomolecules, which are then screened inside the cell for activity (see Scheme 1). On of 
the main advantages of this novel approach is that all the processes (i.e. biosynthesis of the library 
and screening) happen inside a living cell and therefore no in vitro screening is required, thus 
speeding the screening process. Moreover, the fact that the screening process takes place in a 
complex media composed by thousand of proteins (i.e. inside the cytoplasma’s cell) favors the 
selection of  members of the library with high specificity for the target will be selected. This will 
minimize the selection of universal binders, a real problem when in vitro screening methods are 
employed. 
We have used this approach for finding inhibitors agains LF factor from anthrax. This 
protein is a Zn-protease that, once inside the cell, degrades some key host proteins thus disabling 
the host targeted cell.4,5 The fact that this toxin, as well as the microorganism that produce it, can 
be used for bioterrorism or biochemical warfare constitute a major threat to our national security. 
For this reason there is also 
an urgent need to produce 
small, chemically stable and 
readily available inhibitors 
for this or similar toxins. 
Technical plan 
Key to our combinatorial 
approach is the use of a 
library of living cells. Each 
individual cell within this 
living library will produce a 
unique small drug-like 
biomolecule. This 
compound will be then 
screened inside the same 
cell for activity against the 
corresponding molecular 
target, in this case anthrax 
LF. Therefore, this approach 
requires the development of 
in vivo methods for the 
biosynthesis of libraries as well as ways to screen the activity of those molecules in vivo and 
report the activity.  
Biosynthesis of circular polypeptides. Circular peptides are one the most common scaffolds used 
in nature to produce high affinity drug-like effectors (eg. antibiotics, immuno-supressants, etc). 
Figure 1. Protein splicing is new tool that allows to do protein chemistry 
inside living cells. 
Indeed, peptide cyclization is commonly used in medicinal chemistry for modifying the 
properties of bioactive peptides.6,7 In particular, backbone (head-to-tail) cyclization has been 
widely used to rigidify peptide structure, therefore minimizing the entropic cost of receptor 
binding, and to improve the in vivo stability of peptides.  
Circular peptides will be biosynthesized inside the cell by using recombinant DNA expression 
techniques, which will allow us to create vast libraries of these compounds. The circularization of 
the peptide libraries will be accomplished by making use of protein splicing,8-10 a naturally 
occurring process which involves the 
splicing of polypeptide sequences after 
the translation step (see Fig.1). This 
process is mediated by an intein 
domain (red sequence in Fig. 1) and it 
can happen in cis8,10-12 or trans9,13,14 
(see Fig. 2).  
The first approach uses an engineered 
intein unit and a leading polypeptide 
sequence to introduce a C-terminal α-
thioester and a N-terminal Cys residue 
at the peptide sequence to be cyclized, 
respectively. These two chemical 
moieties can react with each other to 
yield the corresponding circular 
peptide (Fig. 2A). The second 
approach is based on the use of protein 
trans-splicing  (Fig. 2B). In this case 
the N-terminal and C-terminal intein 
fragments are fused to the C- and N-
terminus of the peptide to be cyclized, 
respectively. Thus, when the 
corresponding chimeric precursor is 
expressed, the two intein fragments are 
able to associate spontaneously 
allowing protein splicing to occur. 
This event produces the circularization 
of the corresponding peptide sequence.  
Library design. The molecular library 
has designed using the cyclotide 
scaffold as template. Cyclotides are a 
new emerging family of large cyclic 
polypeptides (≈30 residues long) that 
share a disulfide-stabilized core (3 disulfide bonds) with an unusual knotted structure  (Figure 
3).15 Cyclotides contrast with other circular poylpeptides in that they have highly defined three-
dimensional structures, and despite their small size, can be considered as miniproteins. Their 
unique circular backbone topology and knotted arrangement of the 3 disulfide bonds makes them 
exceptionally stable to thermal and enzymatic degradation.15 Furthermore, their well defined 
structures have been also associated with a range of biological activities, including uterotonic 
activity, inhibition of neurotension binding, hemolytic, anti-HIV, insecticidal as well as trypsin 
inhibitory activity. Altogether, these characteristics makes cyclotides ideal candidates to be used 
as molecular scaffolds for new ligand/drug design and discovery.15 
In vivo screening. The screening process for finding which cyclotides within the library are able 
to inhibit LF factor toxin has been carried out using a fluorescence-based reporter16 (see Scheme 
 
Figure 2. Biosynthesis of circular peptides can be achieved by 
engineering protein splicing (A) or by using protein trans-
splicing (B). 
2). LF is a Zn-protease that cleave specific 
proteins crucial for the survival of the 
targeted cell.4,5 Our fluorescence-based 
screening reporter uses the catalytic 
activity of the enzyme in combination with 
a fluorogenic substrate (see Scheme 2).  
The fluorogenic substrate is composed by 
a short peptide containing the natural 
substrate of the protease and flanked by 
two fluorescent proteins. Cyan fluorescent 
protein (CFP) and yellow fluorescent 
protein (YFP) are both engineered mutants 
of the natural occurring green fluorescent 
protein (GFP) and are designed to form a 
FRET (fluorescence resonance energy 
transfer) pair.16 Thus, when the protease 
and the fluorogenic substrate are expressed 
in a cell that has biosynthesized an active (i.e. inhibitor) cyclic peptide, the protease is inhibited 
and therefore unable to cleave the fluorogenic substrate thus allowing the FRET signal to be 
observed, i.e. emission of the YFP fluorophore when exciting the CFP fluorophore. On the other 
hand if the cyclic peptide is inactive against LF the still active protease cleaves the fluorogenic 
substrate leading to the loss of the FRET signal. This in vivo FRET-based inhibition assay will 
allow the selection of the individual cells that are expressing active (i.e. inhibitor) compounds 
from the ones that are not. For this purpose we will use a flow cytometric screening technique 17.. 
Combination of both techniques will provide a powerful living combinatorial tool for finding 
inhibitors against bacterial toxins. Both approaches, i.e. biosynthesis of libraries with in vivo 
screening methods, will be combined as depicted in Scheme 3. The first step involves the creation 
of a combinatorial library of plasmids (in excess of 109 members). All the plasmids of the library 
contain the DNA coding for the proteolytic domain of the protein toxin and the corresponding 
fluorogenic substrate for the corresponding toxin. In addition, any individual plasmid contains a 
variable DNA sequence codifying for the different cyclotides present on the library. This variable 
sequence is fused to the appropriate engineered intein element in order to allow its cyclization 
once expressed inside the cell. 
It is important to note that although this approach has been initially used for finding inhibitors of 
bacterial toxins with enzymatic activity, such as LF, the in vivo biosynthesis/screening approach 
is general. Thus, it is expected that the introduction of slight modifications on the screening 
scheme would be able to provide a truly generic method based on darwinian selection.18-20 This 
Scheme 2. Principle of a chameleon reporter for finding Anthrax Lethal Factor 
inhibitors. 
Figure 3. Schematic of a cyclotide showing conserved 
residues (green), cysteine residues (yellow) and variable 
residues (blue) along with the three dimensional structure of 
a cyclotide. The variable residues will be randomized in the 
library. 
slightly modified approach could be easily used for finding small cyclic peptides that could act as 
effective inhibitors on any protein-protein interaction, thereby providing a general approach for 
discovering new pharmaceutical compound leads. 
Results 
During the duration of this project we have been able to accomplish the biosynthesis of several 
cyclic peptides (cyclotides Kalata B1 and MCoTI-II and sunflower trypsin inhibitor SFTI-I) 
inside E. coli cells as well as a FRET-based screening for reporting LF activity inside living cells. 
Biosynthesis of cyclic peptide based libraries in vivo. Our approach for the biosynthesis of 
circular polypeptides is based on the use 
of an intramolecular version of the native 
chemical ligation combined with the use 
of a modified protein splicing unit.10,21 In 
order to accomplish the cyclization, the 
different linear precursors were fused at 
the N-terminus with a Met residue, and at 
the C-terminus with either a VMA or 
Gyrase engineered inteins (available in 
the pTYB and pTXB expression vectors 
family from New England Biolabs). In 
all the cases the Met residue was 
efficiently removed in vivo by the 
endogenous Met amino peptidase of E. 
coli. This in vivo proteolytic event 
unmasked the required N-terminal Cys 
residue that can then react in an 
intramolecular fashion with the α-thioester generated by the engineered intein at the C-terminus 
of the linear polypeptide precursor. In the case of cyclotide MCoTI-II and SFTI-1 peptide, the 
corresponding circular reduced polypeptides were able to fold spontaneously in the cytoplasm to 
adopt the native structure (Fig. 4A and 4B). We have recently shown that totally reduced cyclic 
Kalata B1 (KB1) can also fold efficiently into its native form under conditions similar to those 
found in the cytoplasm.22 Using this biosynthetic approach we have also produced a small library 
based on the KB1 and SFTI-1 scaffolds (Fig. 5C). Structural characterization for the cyclotides 
KB1 and MCoTI-II was accomplished using standard 2D-homonuclear NMR techniques.22 The 
biological activity of MCoTI-II and SFTI-1 was tested using a trypsin inhibitory assay. In both 
cases the obtained Ki values were similar to those reported for the corresponding natural 
products,23,24 around 20 nM for SFTI-I and 25 pM for MCoTI-II  
In vivo FRET-based reporter for LF activity. Our in vivo FRET-based reporter for LF was 
designed to contain the natural substrate of LF flanked by two fluorescent proteins, cyan 
fluorescent protein (CFP) and yellow fluorescent protein (YFP) 25 (Figure 4D). This reporter 
protein was readily expressed in E. coli showing high levels of FRET in vivo the absence of LF. 
On the other hand, the FRET signal was significantly reduced when LF and the FRET-based 
reporter protein were sequentially expressed in E. coli (Fig. 4D). 
Scheme 3 
  
Figure 4. A. In vivo biosynthesis of backbone cyclized polypeptides using engineered protein splicing units. B. In vivo 
biosynthesis of cyclotide MCoTI-II and trypsin inhibitor SFTI-1. Analytical HPLC traces of different cellular lysates 
after being purified on a trypsin-column. The asterisk indicates the corresponding oxidized cyclic product. C. In vivo 
biosynthesis of cyclotide- and SFTI-based libraries. Left panel, analytical HPLC trace of a KB1-based library. Right 
panel, ES-MS trace of a SFTI-1 library encoding different Ala mutants. D. FRET-based reporter to screen for LF 
activity in side living E. coli cells. 
 
In vivo biosynthesis of ramdonly generated cyclotide-based libraries. Randomly generated 
cyclotide-based libraries were created at the DNA level using double stranded DNA inserts with 
degenerated sequences for some of the different loops of the cyclotide scaffold (i.e. loops 2, 3 
and/or 5, see figure 4A).  
Among the different strategies that have been developed to produce clonable degenerated DNA 
sequences 26-28 we have used method described by Scott and Smith 29 (Fig. 5). This approach 
involves the generation of a double-stranded degenerated DNA by PCR. Briefly, a long 
degenerated synthetic oligonucleotide (which codes the whole cyclotide, ≈ 100 nt long) template 
was PCR amplified using 5’- and 3’-primers corresponding to the non degenerated flanking 
regions. The resulting double stranded degenerated DNA was double digested and a then ligated 
to a linearized intein expression vector (pTXB or pTYB family) to produce a library of plasmids. 
These libraries were then transformed into electrocompetent E. coli cells to finally obtain a 
library of cells containing typically up to ≈109 different clones (i.e. cyclotide sequences). 
The degenerated synthetic oligonucleotide template were synthesized using a NN(G/T) codon 
scheme for the degenerated regions. This scheme uses 32 codons to encode all 20 amino acids 
and encodes only 1 stop codon. Alternatively, the degenerated template was also synthesized 
from mixtures of trinucleotide codons representing all 20 amino acids and no stop codons 30. 
The first cyclotide-based libraries 
generated using this protocols were 
based on loops 2 and/or 5 using the 
cyclotides Kalata B1 and MCoTI-II 
as scaffolds. The complexity of these 
libraries was around ≈106 and ≈109 
members for combinations involving 
only one of the loops or two loops, 
respectively. 
Strategic Aligment  
This project introduces a totally new 
approach for the rapid production and 
screening of high affinity ligands 
against any molecular target thus 
revolutionazing the efforts in national 
biosecurity and drug-discovery at the 
LLNL. These ligands could be used 
as powerful antidotes against any 
particular toxin, but also and more 
importantly, as biosensors when 
attached to appropriate platforms. 
Thus, the whole project aligns 
extremely well with the National 
Institute of Allergy and Infectious Diseases (NAIAD) strategic plan for biodefense research 31 and 
the LLNL responsibilities in homeland security. 
Exit Plan 
We have submitted during FY06 two research proposals requesting funding to continue this 
exciting project: 
1) Department of Defense, Congressionally Directed Medical Research Programs, 
Breast Cancer Program, Idea Award. 
Title: A new combinatorial approach for the generation of small cyclic peptide 
antagonists of the MDM2 oncoprotein as anticancer agents 
Funds requested: 600K in 2 years. 
2) JSTO FY2007 call basic research program in chemical, biological, radiological 
and nuclear defense  of the joint science and technology office physical science and 
technology, Division Defense Threat Reduction Agency (DTRA) 
Title: A cell-based approach for the rapid biosynthesis/screening of cyclic peptide 
libraries against bacterial toxins. 
Funds requested: 862K for 3 years. 
Summary 
In summary we report here the first biosynthesis, using DNA recombinant techniques, of different 
circular Cys-containing peptides in E. coli, including the cyclotide MCoTI-II and the Bowman-
Birk sunflower trypsin inhibitor (SFTI-1). We have also shown that our biosynthetic approach 
can be used to generate cyclotide- and SFTI-based libraries that could be screened in vitro or in 
vivo. Finally, we have also developed a new cell-based FRET reporter for the in vivo screening of 
LF inhibitors. Future work will focus in the screening of cyclotide- and SFTI-based libraries 
against LF using our FRET-based reporter in vivo. 
The development of this novel living combinatorial approach introduces a generic technology that 
combines chemistry and biology for fast and efficient identification of high-specific ligands to 
biological toxins. These ligands can be used as powerful antidotes against toxins. It is also 
anticipated that due to the high stability and high specificity of cylotide-based antidotes they 
Figure 5. Schematic strategy for assembling a double stranded 
DNA coding for a full-length cyclotide with degenerated inserts for 
loops 2 and 5. 
could also be used as reliable and resistant biosensors when attached to the appropriate platforms, 
thus providing cheap and reliable detector systems that can be used to improve response 
capability to bioterrorist attacks on the military as well as on the civilian population. 
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